[Experience with imipenem/cilastatin sodium in the field of obstetrics and gynecology].
Fundamental and clinical studies on a new carbapenem antibiotic, imipenem/cilastatin sodium (MK-0787/MK-0791), were carried out in the field of obstetrics and gynecology. The following results were obtained. The concentration of MK-0787 in uterine tissue was 3.5 approximately 8.2 micrograms/g at about 30 minutes after an administration of 0.5 g/0.5 g of MK-0787/MK-0791 by a 30-minute intravenous drip infusion. The concentration decreased to less than 0.5 microgram/g by approximately 3 hours. The level of MK-0787 in the pelvic dead space exudate reached a peak of 24.0 +/- 4.4 micrograms/ml at 1 hour after an administration of MK-0787/MK-0791 0.5 g/0.5 g and was higher than the plasma level at 1 hour. The level in the pelvic dead space exudate was 2.0 +/- 0.8 microgram/ml at about 6 hours. The MK-0787/MK-0791 was administered to 4 patients with gynecologic infections (2 patients with pelvic peritonitis, 1 patient with salpingitis, 1 patient with a vulvar abscess). The clinical efficacy was good in all 4 patients. Neither adverse effects nor abnormal laboratory findings were observed. It appears that MK-0787/MK-0791 is a safe and useful antibiotic for the treatment of obstetrical and gynecological infections.
Kohara
T
T
Matsui
Y
Y
Noda
M
M
Ooiwa
K
K
Iida
S
S
D000038:Abscess / Q000188:drug therapy; D000328:Adult; D015377:Cilastatin; D003521:Cyclopropanes / Q000008:administration & dosage* / Q000378:metabolism; D004338:Drug Combinations; D005260:Female; D005836:Genitalia, Female / Q000378:metabolism*; D006801:Humans; D015378:Imipenem; D008875:Middle Aged; D010388:Pelvis; D010538:Peritonitis / Q000188:drug therapy; D012488:Salpingitis / Q000188:drug therapy; D013845:Thienamycins / Q000008:administration & dosage* / Q000378:metabolism; D014845:Vulvar Diseases / Q000188:drug therapy
D003521:Cyclopropanes; D004338:Drug Combinations; D013845:Thienamycins; D015377:Cilastatin; D015378:Imipenem